Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

The pharmacology of ambroxol--review and new results.

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

Coupling nutrient sensing to metabolic homoeostasis: the role of the mammalian target of rapamycin complex 1 pathway

Mtor Signaling in Cardiometabolic Disease, Cancer, and Aging

Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases

Mtorc1 Signaling in Hepatic Lipid Metabolism

mTORC1 in energy expenditure: consequences for obesity

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

mTOR Signaling in Metabolic Stress Adaptation

Plasma-assisted ignition and combustion of pulverized coal at thermal power plants of Kazakhstan

Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer

The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Nutrient regulation of mTORC1 at a glance

Adipocyte-specific deletion of mTOR inhibits adipose tissue development and causes insulin resistance in mice

Challenges for high voltage testing of UHV equipment

mTOR Signaling in Growth Control and Disease

The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism

Alterations to Mtorc1 Signaling in the Skeletal Muscle Differentially Affect Whole-Body Metabolism.